Clinical Trial Update: LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating LPM6690176 in combination with chemotherapy and bevacizumab for metastatic colorectal cancer w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• LPM6690176 (LPM6690176)

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Metastatic Colorectal Cancer (mCRC) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING